BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 20151938)

  • 21. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
    Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
    J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
    Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
    Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
    Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
    Blecharz P; Szatkowski W; Klimek M; Urbański K
    Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.
    Beristain E; Martínez-Bouzas C; Guerra I; Viguera N; Moreno J; Ibañez E; Díez J; Rodríguez F; Mallabiabarrena G; Luján S; Gorostiaga J; De Pablo JL; Mendizabal JL; Tejada MI
    Breast Cancer Res Treat; 2007 Dec; 106(2):255-62. PubMed ID: 17262179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
    Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
    J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
    Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J
    Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
    Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
    Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
    Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.